Rodney James Williams, a director of Zomedica Corp., filed a Form 4 on November 18, 2026, disclosing the acquisition of Stock Appreciation Rights in the company on November 16, 2026.
Key Highlights
- Reporting person: Rodney James Williams, listed as a Director of Zomedica Corp.
- Security acquired: 1,975,033 Stock Appreciation Rights (SARs) acquired on November 16, 2026, via transaction code A.
- Exercise price: The conversion or exercise price of the SARs is $0.10, with a price of the derivative security listed as $0.
- Expiration date: The SARs are exercisable beginning November 15, 2027, and expire on November 15, 2036.
- Post-transaction holdings: Following the transaction, Williams directly holds 1,975,033 SARs, with underlying common shares totaling 1,975,033.
- Issuer trading symbol: The filing identifies the issuer as Zomedica Corp. with ticker ZOMDF, as stated on the form.
Williams Acquires Stock Appreciation Rights in Zomedica Corp.
According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 18, 2026, Rodney James Williams, identified as a Director of Zomedica Corp. (ZOMDF), acquired 1,975,033 Stock Appreciation Rights on November 16, 2026. The filing records the transaction under code "A," indicating an acquisition. Williams's address on file is 1101 Technology Drive, Suite 100, Ann Arbor, Michigan 48108.
The filing discloses that the SARs carry a conversion or exercise price of $0.10 and were acquired at a price of $0 for the derivative security itself. The rights are tied to Zomedica common shares on a one-for-one basis, with 1,975,033 underlying common shares noted. Per the filing, the SARs become exercisable on November 15, 2027, and carry an expiration date of November 15, 2036, giving a potential exercise window of approximately nine years from the vesting date.
Following the reported transaction, the filing indicates Williams directly holds 1,975,033 SARs. No non-derivative securities transactions appear in Table I of the filing. The form was signed by Rodney J. Williams and dated November 18, 2026. No amendment date was provided, indicating this is an original filing. The filing was made by one reporting person and does not indicate a joint or group filing.
What Was Disclosed
The filing reports that Director Rodney James Williams acquired 1,975,033 Stock Appreciation Rights in Zomedica Corp. on November 16, 2026, exercisable from November 15, 2027, through November 15, 2036, at an exercise price of $0.10, with direct beneficial ownership of 1,975,033 SARs following the transaction.



Please wait processing your request...